In a medical first, a research team in China has successfully stitched a CRISPR gene-edited pig liver into a brain-dead ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication ...

An organ procurement organization filed a lawsuit to stop Atrium Health from taking over organ donation services at Atrium ...

ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA ...

More than a year after its suspension, the heart transplant program at Richmond (Va.) VA Medical Center is under ...

It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced financial results ...

SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ ... pathology assessments after dosing indicated successful T cell engraftment in lymphoid organs and no signs of compound-induced ...